State-of-the-art management of hypertrophic cardiomyopathy in children

Cardiology in the Young

Volumn 19, Issue SUPPL.2, 2009, Pages 66-73

  Berger, Stuart ^a   Dhala, Anwer ^a   Dearani, Joseph A ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Left ventricular hypertrophy; Myomectomy

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DISOPYRAMIDE; INOTROPIC AGENT; VERAPAMIL;

ACADEMIC ACHIEVEMENT; ATRIOVENTRICULAR BLOCK; AUTOSOMAL DOMINANT INHERITANCE; CHILD GROWTH; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DEFIBRILLATOR; DEPRESSION; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; GENE MUTATION; GENETIC SCREENING; HEART SURGERY; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LUNG EDEMA; PEDIATRIC CARDIOLOGY; PREVALENCE; PROGNOSIS; SIDE EFFECT; SINUS ARREST; SUDDEN DEATH; SURGICAL TECHNIQUE; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME;

ADOLESCENT; CARDIAC SURGICAL PROCEDURES; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; CLINICAL PROTOCOLS; DEATH, SUDDEN, CARDIAC; GENETIC TESTING; HUMANS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 76449113534     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951109991648     Document Type: Conference Paper

References (36)

1. Maron BJ. Hypertrophic cardiomyopathy in childhood. In Pediatric Clinics of North America 51 (2004): 1305-1346.
2. Ganame J, Pignatelli RH, Eidem BW, et al. Myocardial deformation abnormalities in pediatric hypertrophic cardiomyopathy: are all etiologies identical? Eur J Echocardiogr 2008; 9 (6): 784-790; Epub 2008 Apr 27.
3. Morita H, Rehm HL, Mennices A. Shared genetic causes of cardiac hypertrophy in children and adults. NEJM 2008; 358 (18): 1899-1908; Epub 2008 Apr 9.
4. Bos JM, Ommen SR, Ackerman MJ. Genetics of hypertrophic cardiomyopathy: one, two, or more diseases? Curr Opinion Cardiol 2007; 22 (3): 193-199.
5. Maron BJ, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999: 281-650-655.
6. Maron BJ. Echocardiographic assessment of left ventricular hypertrophy in patients with obstructive or nonobstructive hypertrophic cardiomyopathy. Eur Heart J 1983; 4 Suppl F: 73-91.
7. Rawlins J, Bahn A, Sharma S. Left ventricular hypertrophy in athletes. Eur J Echocardiograph 2009; 10 (3): 350-356; Epub 2009 Feb 26.
8. Maron BJ, Spirito P, Wesley , et al. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. NEJM 1986; 315: 610-614. (Pubitemid 16046974)
9. Maron BJ, Seidman JG, Seidman CE. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 44 (11): 2125-2132.
10. Maron MS, Olivotto I, Betochhi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. NEJM 2003; 348: 295-303. (Pubitemid 36119984)
11. Poutanen T, Tikanoja T, Jaaskelainen P. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the betamyosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes. Am Heart J 2006; 151 (3): 725.e1-725.e9.
12. Sotgia B, Sciagra R, Olivotto I, et al. Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. J Nucl Med 2008; 49 (7): 1090-1096.
13. Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45 (8): 1252-1258.
14. Koffland MJ, Waldstein DJ, Vos J, ten Cate FJ. Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol 1993; 72: 939-943.
15. Maron BJ, Olovetto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000; 102: 858-864.
16. Maron BJ, Shen WK, Link MS, et al. Efficiacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. NEJM 2000; 342: 363-373.
17. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000; 36: 2212-2218.
18. Spirito P, Seidman CE, McKenna WJ, Maron BJ. Management of hypertrophic cardiomyopathy. NEJM 1997; 336: 775-785.
19. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta adrenoceptor antagonisy treatment. J Am Coll Cardiol 1999; 34: 1813-1822.
20. Cairns JA, Connolly SJ, Roberts R, et al. Randomized trial of outcome after myocardial infarction I patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997; 349: 675-682.
21. Julian DJ, Camm AJ, Frangin GA, et al. Randomized trial of effect of amiodarone on mortalityt in patients with left ventricular dysfunction after recent myocardial infarction: AMIAT. Lancet 1997; 349: 667-674.
22. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for arrhythmia. NEJM 1996; 335: 1933-1940.
23. Silka MJ, Kron J, Dunnigan A, Dick M. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. Circulation 1993; 87: 800-807.
24. Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33: 1596-1601.
25. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol 2008; 51: 1685-1691.
26. Nishimura RA, Giuliani ER, Brandenburg RO, et al. Hypertrophic cardiomyopathy. Mayo Clinic Practice of Cardiology, 3rd Edition Chapter 20. In: Giuliani ER, Gersh BJ, McGoon MD, Hayes DL, Schaff HV (eds). Mosby-Year Book Inc., St. Louis, MO, 1996, pp 689-711.
27. Theodoro DA, Danielson GK, Feldt RH, Anderson BJ. Hypertrophic obstructive cardiomyopathy in pediatric patients: Results of surgical treatment. J Thorac Cardiovasc Surg 1996; 112: 1589-1599.
28. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the ACC Task Force on Clinical Expert Consensus Documents and the Committee to Develop an Expert Consensus Document on Hypertrohic Cardiomyopathy. J Am Coll Cardiol 2003; 42: 1687-1713.
29. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287: 1308-1320.
30. Dearani JA, Danielson GK. Septal myectomy for hypertrophic cardiomyopathy. Operative Techniques in Thoracic and Cardiovascular Surgery 2004; 9: 278-292.
31. McKenna WJ, Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47: 532-538.
32. Minakata K, Dearani JA, O'Leary PW, et al. Septal myectomy for obstructive hypertrophic cardiomyopathy in pediatric patients: early and late results. Ann Thorac Surg 2005; 80: 1424-1430.
33. McCully RB, Nishimura RA, Tajik AJ, et al. Extent of clinical improvement after surgical treatment of hypertrophic cardiomyopathy. Circulation 1996; 94: 467-471.
34. Seiler C, Hess OM, Schoenbeck M, et al. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. J Am Coll Cardiol 1991; 17: 634-645.
35. Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46 (3): 470-476.
36. Minaka K, Dearani JA, Nishimura RA, et al. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous papillary muscles or chordae. J Thorac Cardiovasc Surg 2004; 127: 481.